Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on September 17, 2021, reporting a material definitive agreement entered into on that date. The company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol GALT.
Key Financial Metrics and Transaction Details
The filing discloses a new financing arrangement rather than standard periodic financial results. Key metrics include:
- Total Loan Amount: $20,000,000 aggregate principal.
- First Closing: $10,000,000 funded on September 17, 2021.
- Second Closing: Remaining $10,000,000 to be funded on or before December 17, 2021.
- Interest Rate: 2% per annum compounded annually, plus 2.5% per quarter additional interest (payable only upon full conversion).
- Maturity Date: September 17, 2025.
- Conversion Price (First Note): $8.64 per share (228% of the closing price on September 16, 2021).
- Conversion Price (Second Note): Greater of 228% of the closing price prior to the second closing or $5.00.
The filing does not provide current revenue, profit, cash flow, or existing debt levels outside of this new agreement.
Material Changes and Agreements
The primary material change is the entry into a Loan Agreement with Richard E. Uihlein. This transaction includes the following significant terms:
- Termination of Prior Facility: The existing $10 million Line of Credit (dated December 19, 2017, amended January 11, 2019) will be terminated upon the closing of the second $10 million loan in December 2021. There are currently no borrowings under this Line of Credit.
- Security Status: The promissory notes are unsecured.
- Regulatory Exemption: The issuance of the notes is exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D.
Outlook, Risks, and Management Commentary
The filing references a press release issued on September 21, 2021 (Exhibit 99.1) for further details but does not contain explicit forward-looking guidance, risk factors, or management commentary within the text of this 8-K. The structure of the loan, specifically the high conversion premium (228%), suggests a strategy to secure immediate liquidity while deferring equity dilution until a future conversion event.
Investor Verification Checklist
- Verify the exact closing date and funding receipt of the second $10 million tranche scheduled for December 2021.
- Review the full text of the Loan Agreement (Exhibit 10.1) and Promissory Note (Exhibit 10.2) for covenants, default provisions, and specific conditions regarding the "Additional Interest."
- Confirm the current cash position of the company to assess the immediate impact of the $10 million funding.
- Monitor the stock price relative to the $8.64 conversion price to evaluate the likelihood of conversion versus cash repayment at maturity.
- Check the September 21, 2021 press release (Exhibit 99.1) for any additional context on the use of proceeds.